Corcept says ADA and EASD recommend hypercortisolism screening in difficult-to-control type 2 diabetes, citing CATALYST trial

Corcept Therapeutics says the ADA and EASD recommend hypercortisolism screening in difficult-to-control type 2 diabetes, citing its CATALYST mifepristone trial.

Detected & updated continuously · Source: Nebula